Evidence map›Paper›PMID 39369132›Full record

ArticleArchives of dermatological research2024

Recombinant ISRAA ameliorates imiquimod-induced psoriasis and knocking out Israa delays its onset.

Manahel Mahmood Alsabbagh, Muna Aljishi, Ameera Sultan, Amar Muhsin Marwani, Nasneen Althaf, Moiz Bakhiet, Safa Taha

Abstract read
PubMed Publisher
In one paragraph

Article in Archives of dermatological research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Manahel Mahmood AlsabbaghPrincess Al-Jawhara Center for Molecular Medicine and Inherited Disorders, Department of Molecular Medicine, College of Medicine and Medical Sciences, Arabian Gulf University, P.O. Box 26671, Manama, Kingdom of Bahrain. ManahelAlsabbagh2014@alumnircsi.com.ORCID http://orcid.org/0000-0002-8013-760X
Muna Aljishi *Princess Al-Jawhara Center for Molecular Medicine and Inherited Disorders, Department of Molecular Medicine, College of Medicine and Medical Sciences, Arabian Gulf University, P.O. Box 26671, Manama, Kingdom of Bahrain.ORCID http://orcid.org/0000-0003-1178-8625
Ameera Sultan *Princess Al-Jawhara Center for Molecular Medicine and Inherited Disorders, Department of Molecular Medicine, College of Medicine and Medical Sciences, Arabian Gulf University, P.O. Box 26671, Manama, Kingdom of Bahrain.ORCID http://orcid.org/0000-0002-6660-3627
Amar Muhsin Marwani *Animal Facility Unit, College of Medicine and Medical Sciences, Arabian Gulf University, P.O. Box 26671, Manama, Kingdom of Bahrain.ORCID http://orcid.org/0009-0005-9715-371X
Nasneen Althaf *Animal Facility Unit, College of Medicine and Medical Sciences, Arabian Gulf University, P.O. Box 26671, Manama, Kingdom of Bahrain.ORCID http://orcid.org/0009-0002-8839-0746
Moiz BakhietPrincess Al-Jawhara Center for Molecular Medicine and Inherited Disorders, Department of Molecular Medicine, College of Medicine and Medical Sciences, Arabian Gulf University, P.O. Box 26671, Manama, Kingdom of Bahrain.ORCID http://orcid.org/0000-0002-5148-8849
Safa TahaPrincess Al-Jawhara Center for Molecular Medicine and Inherited Disorders, Department of Molecular Medicine, College of Medicine and Medical Sciences, Arabian Gulf University, P.O. Box 26671, Manama, Kingdom of Bahrain. SafaT@agu.edu.bh.ORCID http://orcid.org/0000-0002-8276-4535

Funding

Arabian Gulf University E033-PI-12/20 (funded as part of ISRAA project)
6 · The paper itself

Abstract

Psoriasis, an inflammatory disease, is largely mediated by T-helper 17 cytokines. We have previously identified the immune system-released activating agent (Israa) as a novel gene that connects the nervous and immune systems. This research aims to investigate the role of the Israa gene in psoriasis in vivo using the imiquimod-induced psoriasis model. We established the model in C57BL/6 wildtype mice, which were then treated with 200 pg/mouse, 400 pg/mouse, or 800 pg/mouse of recombinant ISRAA compared to methotrexate. Subsequently, we also induced psoriasis in Israa-knockout mice to confirm the effect of Israa. Results consistently showed improvement in psoriasis in all groups receiving recombinant ISRAA. The 200 pg/mouse dose eliminated the disease, reduced the cutaneous release of IL-17 to one-third and TNF-α to one-sixth, increased IL-10 release to over 500 pg, completely resolved parakeratosis, decreased epidermal thickness to one-half, and reduced the expression of CD4 and neutrophil elastase in the skin (all p < 0.05). Israa-knockout mice exhibited less severe psoriasis in all scoring, biochemical, and histological parameters compared to wild-type mice (p < 0.05). This study highlights Israa as a crucial molecule in psoriasis and confirms its immunomodulatory role in inflammatory diseases.

Indexed as

Disease Models, AnimalImiquimodPsoriasisAnimalsCD4 AntigensHumansInterleukin-10Interleukin-17Leukocyte ElastaseMethotrexateMiceMice, Inbred C57BLMice, KnockoutRecombinant ProteinsSkinTumor Necrosis Factor-alphaCD4 AntigensIL10 protein, mouseIl17a protein, mouseImiquimodInterleukin-10Interleukin-17Leukocyte ElastaseMethotrexateRecombinant ProteinsTumor Necrosis Factor-alphaIL-10IL-17Inflammatory skin diseaseIsraaPsoriasisPsoriasis pathogenesisPsoriasis treatmentTNF-ɑ

Identifiers

PMID39369132

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.